A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)

References

• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135. doi:10.1038/s41586-021-03398-2
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616–622. doi:10.1038/s41586-021-03324-6
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–675. doi:10.1038/s41586-021-04389-z
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–484.e415. doi:10.1016/j.cell.2021.12.046
   PubMed Web of Science ®Google Scholar
• Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021;29(5):747–751.e744. doi:10.1016/j.chom.2021.04.007
   PubMed Web of Science ®Google Scholar
• McCallum M, Walls AC, Sprouse KR, et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science. 2021;374(6575):1621–1626. doi:10.1126/science.abl8506
   PubMed Web of Science ®Google Scholar
• Yuan M, Huang D, Lee CD, et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021;373(6556):818–823. doi:10.1126/science.abh1139
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Zhou D, Ginn HM, et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021;184(8):2183–2200.e2122. doi:10.1016/j.cell.2021.02.032
   PubMed Web of Science ®Google Scholar
• McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;375(6583):864–868. doi:10.1126/science.abn8652
   PubMed Web of Science ®Google Scholar
• Hastie KM, Li H, Bedinger D, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science. 2021;374(6566):472–478. doi:10.1126/science.abh2315
   PubMed Web of Science ®Google Scholar
• Wang N, Sun Y, Feng R, et al. Structure-based development of human antibody cocktails against SARS-CoV-2. Cell Res. 2021;31(1):101–103. doi:10.1038/s41422-020-00446-w
   PubMed Web of Science ®Google Scholar
• Schoof M, Faust B, Saunders RA, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473–1479. doi:10.1126/science.abe3255
   PubMed Web of Science ®Google Scholar
• Huo J, Le Bas A, Ruza RR, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846–854. doi:10.1038/s41594-020-0469-6
   PubMed Web of Science ®Google Scholar
• Koenig PA, Das H, Liu H, et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021;371:6530. doi:10.1126/science.abe6230
   Web of Science ®Google Scholar
• Wrapp D, De Vlieger D, Corbett KS, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell. 2020;181(5):1004–1015.e1015. doi:10.1016/j.cell.2020.04.031
   PubMed Web of Science ®Google Scholar
• Jovčevska I, Muyldermans S. The Therapeutic Potential of Nanobodies. BioDrugs. 2020;34(1):11–26. doi:10.1007/s40259-019-00392-z
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol. 2017;8:1442. doi:10.3389/fimmu.2017.01442
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–797. doi:10.1146/annurev-biochem-063011-092449
   PubMed Web of Science ®Google Scholar
• Xiang Y, Nambulli S, Xiao Z, et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020;370(6523):1479–1484. doi:10.1126/science.abe4747
   PubMed Web of Science ®Google Scholar
• Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 2002;11(3):500–515. doi:10.1110/ps.34602
   PubMed Web of Science ®Google Scholar
• Esparza TJ, Martin NP, Anderson GP, Goldman ER, Brody DL. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci Rep. 2020;10(1):22370. doi:10.1038/s41598-020-79036-0
   PubMed Web of Science ®Google Scholar
• Ikeuchi E, Kuroda D, Nakakido M, Murakami A, Tsumoto K. Delicate balance among thermal stability, binding affinity, and conformational space explored by single-domain V(H)H antibodies. Sci Rep. 2021;11(1):20624. doi:10.1038/s41598-021-98977-8
   PubMed Web of Science ®Google Scholar
• Zhang X, Meining W, Fischer M, Bacher A, Ladenstein R. X-ray structure analysis and crystallographic refinement of lumazine synthase from the hyperthermophile Aquifex aeolicus at 1.6 A resolution: determinants of thermostability revealed from structural comparisons. J Mol Biol. 2001;306(5):1099–1114. doi:10.1006/jmbi.2000.4435
   PubMed Web of Science ®Google Scholar
• Wörsdörfer B, Pianowski Z, Hilvert D. Efficient in vitro encapsulation of protein cargo by an engineered protein container. J Am Chem Soc. 2012;134(2):909–911. doi:10.1021/ja211011k
   PubMed Web of Science ®Google Scholar
• Seebeck FP, Woycechowsky KJ, Zhuang W, Rabe JP, Hilvert D. A simple tagging system for protein encapsulation. J Am Chem Soc. 2006;128(14):4516–4517. doi:10.1021/ja058363s
   PubMed Web of Science ®Google Scholar
• Ra JS, Shin HH, Kang S, Do Y. Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development. Clin Exp Vaccine Res. 2014;3(2):227–234. doi:10.7774/cevr.2014.3.2.227
   PubMedGoogle Scholar
• Zakeri B, Fierer JO, Celik E, et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A. 2012;109(12):E690–697. doi:10.1073/pnas.1115485109
   PubMed Web of Science ®Google Scholar
• Li L, Fierer JO, Rapoport TA, Howarth M. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide Tag. J Mol Biol. 2014;426(2):309–317. doi:10.1016/j.jmb.2013.10.021
   PubMed Web of Science ®Google Scholar
• Tan TK, Rijal P, Rahikainen R, et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun. 2021;12(1):542. doi:10.1038/s41467-020-20654-7
   PubMed Web of Science ®Google Scholar
• Rahikainen R, Rijal P, Tan TK, et al. Overcoming symmetry mismatch in vaccine nanoassembly through spontaneous amidation. Angew Chem Int Ed Engl. 2021;60(1):321–330. doi:10.1002/anie.202009663
   PubMed Web of Science ®Google Scholar
• Bruun TUJ, Andersson AC, Draper SJ, Howarth M. Engineering a rugged nanoscaffold to enhance plug-and-display vaccination. ACS Nano. 2018;12(9):8855–8866. doi:10.1021/acsnano.8b02805
   PubMed Web of Science ®Google Scholar
• Brune KD, Leneghan DB, Brian IJ, et al. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep. 2016;6:19234. doi:10.1038/srep19234
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang F, Lu Y, et al. Highly potent multivalent VHH antibodies against Chikungunya isolated from an alpaca naïve phage display library. J Nanobiotechnology. 2022;20(1):231. doi:10.1186/s12951-022-01417-6
   PubMed Web of Science ®Google Scholar
• Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020;15(11):3699–3715. doi:10.1038/s41596-020-0394-5
   PubMed Web of Science ®Google Scholar
• Lu Q, Zhang Z, Li H, et al. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. J Nanobiotechnology. 2021;19(1):33. doi:10.1186/s12951-021-00768-w
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124. doi:10.1038/s41586-020-2381-y
   PubMed Web of Science ®Google Scholar
• Hanke L, Vidakovics Perez L, Sheward DJ, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun. 2020;11(1):4420. doi:10.1038/s41467-020-18174-5
   PubMed Web of Science ®Google Scholar
• Li W, Schäfer A, Kulkarni SS, et al. High potency of a bivalent human V(H) Domain in SARS-CoV-2 animal models. Cell. 2020;183(2):429–441.e416. doi:10.1016/j.cell.2020.09.007
   PubMed Web of Science ®Google Scholar
• Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073–1078. doi:10.1038/s41587-020-0631-z
   PubMed Web of Science ®Google Scholar
• Abe KT, Li Z, Samson R, et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight. 2020;5:19. doi:10.1172/jci.insight.142362
   Web of Science ®Google Scholar
• Graef RR, Anderson GP, Doyle KA, et al. Isolation of a highly thermal stable lama single domain antibody specific for Staphylococcus aureus enterotoxin B. BMC Biotechnol. 2011;11:86. doi:10.1186/1472-6750-11-86
   PubMed Web of Science ®Google Scholar
• Turner KB, Zabetakis D, Legler P, Goldman ER, Anderson GP. Isolation and epitope mapping of staphylococcal enterotoxin B single-domain antibodies. Sensors. 2014;14(6):10846–10863. doi:10.3390/s140610846
   PubMed Web of Science ®Google Scholar
• Olson MA, Legler PM, Zabetakis D, Turner KB, Anderson GP, Goldman ER. Sequence tolerance of a single-domain antibody with a high thermal stability: comparison of computational and experimental fitness profiles. ACS Omega. 2019;4(6):10444–10454. doi:10.1021/acsomega.9b00730
   PubMed Web of Science ®Google Scholar
• Li Q, Humphries F, Girardin RC, et al. Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants. Front Immunol. 2022;13:995412. doi:10.3389/fimmu.2022.995412
   PubMed Web of Science ®Google Scholar
• VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490–495. doi:10.1038/s41591-021-01678-y
   PubMed Web of Science ®Google Scholar
• Li C, Zhan W, Yang Z, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 2022;185(8):1389–1401.e1318. doi:10.1016/j.cell.2022.03.009
   PubMed Web of Science ®Google Scholar
• Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630–633. doi:10.1126/science.abb7269
   PubMed Web of Science ®Google Scholar
• Weidenbacher PA, Waltari E. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat Chem Biol. 2022;18(11):1270–1276. doi:10.1038/s41589-022-01140-1
   PubMed Web of Science ®Google Scholar